CSIMarket
 


Cel sci Corporation  (CVM)
Other Ticker:  
 

Cel Sci's Quick Ratio

CVM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Cel Sci's Cash & cash equivalent grew by 54531.35 % in the I Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Cel Sci's Quick Ratio to 0.48, Quick Ratio remained below Cel sci Corporation average.

Within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Quick Ratio than Cel Sci in first quarter 2023. While Quick Ratio total ranking has improved so far during the I Quarter 2023 to 947, from total ranking in the forth quarter 2023 at 4587.

Explain Quick Ratio?
How much Cash & cash equivalents CVM´s has?
What are CVM´s Current Liabilities?


CVM Quick Ratio (Dec 31 2023)
I. Quarter
(Sep 30 2023)
IV. Quarter
(Jun 30 2023)
III. Quarter
(Mar 31 2023)
II. Quarter
(Dec 31 2022)
I. Quarter
Y / Y Current Liabilities Change 2.64 % 19.77 % 31.8 % 18.72 % 42.25 %
Y / Y Cash & cash equivalent Change -87.13 % -99.98 % -73.45 % -63.93 % -51.45 %
Quick Ratio MRQ 0.48 0 1.41 2.33 3.8
CVM's Total Ranking # 947 # 4587 # 1497 # 1178 # 297
Seq. Current Liabilities Change -12.86 % 5.54 % -0.37 % 12.02 % 1.67 %
Seq. Cash & cash equivalent Change 54531.35 % -99.94 % -39.72 % -31.37 % -20.53 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 187
Overall Market # 947


Quick Ratio Statistics
High Average Low
11.21 3.08 0
(Sep 30 2021)   (Sep 30 2023)




Financial Statements
Cel Sci's Current Liabilities $ 5 Millions Visit CVM's Balance sheet
Cel Sci's Cash & cash equivalent $ 2 Millions Visit CVM's Balance sheet
Source of CVM's Sales Visit CVM's Sales by Geography


Cumulative Cel Sci's Quick Ratio

CVM's Quick Ratio for the trailling 12 Months

CVM Quick Ratio

(Dec 31 2023)
I. Quarter
(Sep 30 2023)
IV. Quarter
(Jun 30 2023)
III. Quarter
(Mar 31 2023)
II. Quarter
(Dec 31 2022)
I. Quarter
Y / Y Current Liabilities TTM Growth 2.64 % 19.77 % 31.8 % 18.72 % 42.25 %
Y / Y Cash & cash equivalent TTM Growth -87.13 % -99.98 % -73.45 % -63.93 % -51.45 %
Quick Ratio TTM 1.05 1.81 3.02 4.33 5.76
Total Ranking TTM # 341 # 2166 # 538 # 3772 # 3528
Seq. Current Liabilities TTM Growth -12.86 % 5.54 % -0.37 % 12.02 % 1.67 %
Seq. Cash & cash equivalent TTM Growth 54531.35 % -99.94 % -39.72 % -31.37 % -20.53 %


On the trailing twelve months basis Due to fall in Current Liabilities in the I Quarter 2023 to $4.87 millions, cumulative Quick Ratio decreased to 1.05 below the Cel Sci Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Quick Ratio than Cel Sci. While Quick Ratio overall ranking has improved so far to 341, from total ranking during the twelve months ending forth quarter 2023 at 2166.

Explain Quick Ratio?
How much Cash & cash equivalents CVM´s has?
What are CVM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 12
Healthcare Sector # 71
Within the Market # 341


trailing twelve months Quick Ratio Statistics
High Average Low
9.74 3.52 0.36
(Mar 31 2022)   (Dec 31 2017)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Cyclo Therapeutics Inc   1.24 $ 9.247  Millions$ 7.457  Millions
Pluri Inc   1.21 $ 5.468  Millions$ 4.530  Millions
Adma Biologics Inc   1.06 $ 51.352  Millions$ 48.579  Millions
Halozyme Therapeutics Inc   1.05 $ 118.370  Millions$ 112.494  Millions
Bio techne Corp  1.00 $ 135.652  Millions$ 135.231  Millions
Sangamo Therapeutics Inc   0.95 $ 45.204  Millions$ 47.731  Millions
Valneva Se  0.79 $ 141.210  Millions$ 177.927  Millions
Elutia inc   0.63 $ 19.276  Millions$ 30.390  Millions
Champions Oncology Inc   0.61 $ 4.468  Millions$ 7.335  Millions
Amgen Inc   0.60 $ 10,944.000  Millions$ 18,392.000  Millions
Protalix Biotherapeutics inc   0.52 $ 23.634  Millions$ 45.530  Millions
Coeptis Therapeutics Holdings Inc   0.50 $ 1.469  Millions$ 2.951  Millions
Cel sci Corporation  0.48 $ 2.319  Millions$ 4.867  Millions
Vaxart Inc   0.36 $ 4.958  Millions$ 13.724  Millions
Coherus Biosciences inc   0.35 $ 117.748  Millions$ 331.771  Millions
Novavax inc  0.35 $ 578.929  Millions$ 1,635.138  Millions
Biocardia Inc  0.31 $ 1.103  Millions$ 3.608  Millions
Zeo Scientifix Inc   0.30 $ 1.179  Millions$ 3.923  Millions
Outlook Therapeutics Inc   0.23 $ 10.357  Millions$ 45.968  Millions
Calidi Biotherapeutics Inc   0.19 $ 1.949  Millions$ 10.232  Millions
Gilead Sciences Inc   0.16 $ 1,179.000  Millions$ 7,478.000  Millions
Kiromic Biopharma Inc   0.16 $ 3.204  Millions$ 20.378  Millions

Date modified: 2024-02-15T15:45:03+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com